The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ERAS | +1.92% | N/A | N/A | -82% |
| S&P | +12.66% | +85.37% | +13.13% | +58% |
Erasca, Inc. is a clinical stage precision oncology company, It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.76M | 10.3% |
| Market Cap | $618.40M | -19.8% |
| Market Cap / Employee | $6.00M | 0.0% |
| Employees | 103 | -18.3% |
| Net Income | -$30.61M | 1.9% |
| EBITDA | -$31.79M | 12.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $70.23M | 2.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $43.41M | -10.5% |
| Short Term Debt | $4.89M | 9.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -26.90% | 6.7% |
| Return On Invested Capital | -47.81% | -2.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$21.66M | 3.4% |
| Operating Free Cash Flow | -$21.66M | 3.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.58 | 0.92 | 0.90 | 1.66 | 0.52% |
| Price to Tangible Book Value | 1.58 | 0.92 | 0.90 | 1.66 | 0.52% |
| Enterprise Value to EBITDA | -13.29 | -3.86 | -3.64 | -11.90 | -14.21% |
| Return on Equity | -43.7% | -45.8% | -31.2% | -32.0% | -20.65% |
| Total Debt | $51.89M | $50.81M | $49.42M | $48.29M | -8.78% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
